FindTrial
Sign In

Prediction of Neoadjuvant Therapy Response in Breast Cancer Based on Interpretable Artificial Intelligence

Prediction of Neoadjuvant Therapy Response in Breast Cancer Based on Interpretable Artificial Intelligence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105600
Enrollment
Unknown
Registered
2025-07-07
Start date
2024-02-21
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Observation group:None

Sponsors

Nanchang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 82 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with breast cancer and meeting the diagnostic criteria specified in the relevant diagnostic guidelines for breast cancer; (2) Received neoadjuvant therapy before surgery.

Exclusion criteria

Exclusion criteria: (1) Combined with other malignancies; (2) Breast cancer treated by other methods; (3) Incomplete clinical or pathological data

Design outcomes

Primary

MeasureTime frame
Residual Cancer Burden,RCB;Estrogen Receptor,ER;Progesterone Receptor,PR;Androgen Receptor,AR;Human Epidermal growth factor Receptor 2,HER2;Ki-67 antigen;—

Secondary

MeasureTime frame
age;gender;The site of tumor presentation;—

Countries

China

Contacts

Public ContactYao Zhou

Nanchang People's Hospital

zhouyaoican@163.com+86 138 7916 8691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026